Latest On BiondVax Pharmaceuticals Ltd (BVXV):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-15 19:53 EST | News | Biondvax Pharmaceuticals GAAP EPS of $0.00 beats by $0.73 | N/A |  |
| 2023-04-18 06:27 EST | News | Biondvax Pharmaceuticals GAAP EPS of -$0.01 beats by $3.42 | N/A | |
| 2022-12-16 16:39 EST | News | BiondVax Pharmaceuticals prices ~$8M underwritten public offering | N/A | |
| 2022-12-01 05:48 EST | News | Biondvax Pharmaceuticals GAAP EPS of NIS0.01 | N/A | |
| 2022-09-30 12:41 EST | News | BiondVax gets Nasdaq non-compliance notice; files for stock offering | N/A | |
| 2022-08-26 00:08 EST | News | Bionvax Pharmaceuticals GAAP EPS of -NIS0.02 | N/A | |
| 2022-08-10 11:17 EST | News | BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan | N/A | |
| 2022-06-07 23:23 EST | News | BiondVax gets supportive scientific advice for its COVID-19 therapy development plans | N/A | |
| 2022-06-01 10:10 EST | News | Biondvax Pharmaceuticals reports Q1 results | N/A | |
| 2022-04-05 20:09 EST | News | BiondVax Pharmaceuticals Ltd.'s (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-04-05 04:36 EST | News | BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-28 11:51 EST | News | Biondvax Pharmaceuticals GAAP EPS of -NIS0.07 | N/A | |
| 2022-03-25 11:24 EST | News | BiondVax stock soars 15% on research pact to develop nanosized antibody therapies | N/A | |
| 2021-12-28 21:38 EST | News | BiondVax soars 35% amid former CFO of GSK's global vaccines business joining board | N/A | |
| 2021-12-27 07:46 EST | News | BiondVax slumps on pricing $9.0 million public offering of ADS | N/A | |
| 2021-12-22 11:01 EST | News | BiondVax gains on collaboration to develop nanosized COVID-19 antibody therapy | N/A | |
| 2021-11-30 18:59 EST | News | Biondvax Pharmaceuticals reports Q3 results | N/A | |
| 2021-10-20 01:09 EST | News | BiondVax rises amid collaboration for VHH antibodies | N/A | |
| 2021-08-27 02:52 EST | News | Biondvax Pharmaceuticals reports Q2 results | N/A | |
| 2021-07-22 17:16 EST | News | Biondvax Pharmaceuticals reports Q1 results | N/A | |
| 2021-02-01 02:13 EST | Financials | Company financials have been released. | Neutral | |
| 2021-01-29 12:26 EST | News | BiondVax Pharmaceuticals under pressure on pricing $12.1M ADSs follow-on offering | N/A | |
| 2021-01-28 19:05 EST | News | Biondvax Pharmaceuticals reports Q3 results | N/A | |
| 2021-01-21 19:44 EST | News | BiondVax announces leadership transition with the appointment of new CEO | N/A | |
| 2020-12-04 06:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-23 18:03 EST | News | Biondvax Pharma's flu vaccine candidate unsuccessful in late-stage study | N/A | |
| 2020-10-08 21:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-04 15:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-02 10:50 EST | News | BiondVax announces ATM equity offering program | N/A | |
| 2020-09-26 16:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-02 05:27 EST | News | BiondVax Pharmaceuticals: A Small, Undervalued Biotech Company | N/A | |
| 2020-08-28 03:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-22 03:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-21 13:57 EST | News | Biondvax Pharmaceuticals reports Q2 results | N/A | |
| 2020-08-21 12:37 EST | Earnings Estimate | An EPS average of -$0.06 is estimated for the 2021 year. | Buy | |
| 2020-08-21 12:37 EST | Earnings Estimate | An EPS average of -$0.01 is estimated for the quarter ending on September 30, 2020. | Buy | |
| 2020-08-14 12:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 12:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 21:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:37 EST | Financials | Company financials have been released. | Neutral | |
About BiondVax Pharmaceuticals Ltd (BVXV):
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
General
- Name BiondVax Pharmaceuticals Ltd
- Symbol BVXV
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 25
- Fiscal Year EndDecember
- IPO Date2015-05-12
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.biondvax.com
View More
Valuation
- Price/Book (Most Recent Quarter) 11.71
View More
Financials
- Most Recent Quarter 2020-09-30
- Return on Assets -8%
- Earnings Per Share -$2.30
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 58.52 million
- Analyst Target Price $81
- Book Value Per Share $0.61
View More
Share Statistics
- Shares Outstanding 13.97 million
- Shares Float 7.83 million
- % Held by Insiders 3710%
- % Held by Institutions 4.06%
- Shares Short 896233
- Shares Short Prior Month 827837
- Short Ratio 0.71
- Short % of Shares Outstanding 6%
View More
Technicals
- Beta 2.28
- 52 Week High $62
- 52 Week Low $2.35
- 50 Day Moving Average 4.59
- 200 Day Moving Average 13.69
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
BiondVax Pharmaceuticals Ltd (BVXV) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
BiondVax Pharmaceuticals Ltd (BVXV) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-01-28 | $0.03 | -$0.01 | 405% | |
| 2020-06-30 | 2020-08-20 | $N/A | -$0.03 | -$0.01 | -194% |
| 2020-03-31 | 2020-06-12 | $N/A | -$0.03 | -$0.01 | -190% |
| 2019-09-30 | 2019-11-26 | $N/A | -$0.01 | -$0.03 | 52% |
| 2019-06-30 | 2019-08-28 | $N/A | -$0.05 | -$0.02 | -155.5% |
| 2019-03-31 | 2019-04-30 | $N/A | -$0.04 | -$0.01 | -289% |
| 2018-12-31 | 2018-12-31 | $N/A | -$0.05 | -$0.01 | -400% |
| 2018-09-30 | 2018-11-13 | $N/A | $-0.00 | -$0.01 | 73% |
| 2018-06-30 | 2018-08-22 | $N/A | -$1.09 | ||
| 2018-03-31 | 2018-05-29 | $N/A | -$0.01 | ||
| 2017-09-30 | 2017-11-28 | $N/A | $0.11 | -$0.19 | 160.16% |
| 2017-06-30 | 2017-08-31 | $N/A | -$0.78 | ||
| 2017-03-31 | 2017-04-28 | $N/A | -$0.18 | -$0.01 | -1700% |
| 2016-09-30 | 2016-11-28 | $N/A | -$0.01 | -$0.01 | 0% |
| 2016-06-30 | 2016-08-18 | $N/A | -$0.20 | ||
| 2016-03-31 | 2016-04-27 | $N/A | -$0.25 | -$0.09 | -177.78% |
| 2015-09-30 | 2015-11-09 | $N/A | $0.01 | -$0.11 | 109.09% |
| 2015-06-30 | 2015-08-10 | $N/A | -$0.14 | -$0.12 | -16.67% |
| 2015-03-31 | 2015-05-15 | $N/A | -$0.35 |
BiondVax Pharmaceuticals Ltd (BVXV) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
BiondVax Pharmaceuticals Ltd (BVXV) Chart:
BiondVax Pharmaceuticals Ltd (BVXV) News:
Below you will find a list of latest news for BiondVax Pharmaceuticals Ltd (BVXV) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
BiondVax Pharmaceuticals Ltd (BVXV) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest BVXV Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 56 | $1.18 |
BiondVax Pharmaceuticals Ltd (BVXV) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020016420/0001213900-20-016420-index.htm |
| 2019-05-30 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1611747/000000000019009179/0000000000-19-009179-index.htm |
| 2020-08-05 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1611747/000000000020007158/0000000000-20-007158-index.htm |
| 2020-01-24 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1611747/000107997320000051/0001079973-20-000051-index.htm |
| 2019-11-12 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1611747/000117891319002662/0001178913-19-002662-index.htm |
| 2019-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390019008673/0001213900-19-008673-index.htm |
| 2019-05-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390019009673/0001213900-19-009673-index.htm |
| 2019-05-30 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1611747/000121390019009767/0001213900-19-009767-index.htm |
| 2019-05-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390019009772/0001213900-19-009772-index.htm |
| 2019-06-06 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1611747/000121390019010133/0001213900-19-010133-index.htm |
| 2019-06-05 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1611747/000121390019010135/0001213900-19-010135-index.htm |
| 2019-06-05 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1611747/000121390019010137/0001213900-19-010137-index.htm |
| 2019-06-07 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1611747/000121390019010278/0001213900-19-010278-index.htm |
| 2019-06-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390019010921/0001213900-19-010921-index.htm |
| 2019-07-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390019012180/0001213900-19-012180-index.htm |
| 2019-07-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390019012184/0001213900-19-012184-index.htm |
| 2019-07-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390019012807/0001213900-19-012807-index.htm |
| 2019-08-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390019016840/0001213900-19-016840-index.htm |
| 2019-10-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390019019930/0001213900-19-019930-index.htm |
| 2019-11-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390019023858/0001213900-19-023858-index.htm |
| 2019-11-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390019024707/0001213900-19-024707-index.htm |
| 2019-12-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390019027267/0001213900-19-027267-index.htm |
| 2020-01-07 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1611747/000121390020000338/0001213900-20-000338-index.htm |
| 2020-01-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020000828/0001213900-20-000828-index.htm |
| 2020-01-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020001166/0001213900-20-001166-index.htm |
| 2020-01-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020001175/0001213900-20-001175-index.htm |
| 2020-02-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020002666/0001213900-20-002666-index.htm |
| 2020-02-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020003063/0001213900-20-003063-index.htm |
| 2020-02-10 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020003126/0001213900-20-003126-index.htm |
| 2020-02-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020004711/0001213900-20-004711-index.htm |
| 2020-03-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020006841/0001213900-20-006841-index.htm |
| 2020-03-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020007261/0001213900-20-007261-index.htm |
| 2020-04-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020010562/0001213900-20-010562-index.htm |
| 2020-05-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020010866/0001213900-20-010866-index.htm |
| 2020-05-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020013023/0001213900-20-013023-index.htm |
| 2020-06-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020014562/0001213900-20-014562-index.htm |
| 2020-06-12 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020014759/0001213900-20-014759-index.htm |
| 2020-06-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020014762/0001213900-20-014762-index.htm |
| 2020-06-22 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1611747/000121390020015429/0001213900-20-015429-index.htm |
| 2020-07-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020016404/0001213900-20-016404-index.htm |
| 2020-07-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020016420/0001213900-20-016420-index.htm |
| 2020-07-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020018857/0001213900-20-018857-index.htm |
| 2020-07-29 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1611747/000121390020019099/0001213900-20-019099-index.htm |
| 2020-08-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020020357/0001213900-20-020357-index.htm |
| 2020-08-06 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1611747/000121390020020577/0001213900-20-020577-index.htm |
| 2020-08-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020022387/0001213900-20-022387-index.htm |
| 2020-08-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020023319/0001213900-20-023319-index.htm |
| 2020-09-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020024662/0001213900-20-024662-index.htm |
| 2020-09-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020024985/0001213900-20-024985-index.htm |
| 2020-10-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020029703/0001213900-20-029703-index.htm |
| 2020-10-02 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020029705/0001213900-20-029705-index.htm |
| 2020-10-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020029707/0001213900-20-029707-index.htm |
| 2020-10-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1611747/000121390020032956/0001213900-20-032956-index.htm |
| 2020-05-13 | 25-NSE | Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or ret | https://www.sec.gov/Archives/edgar/data/1611747/000135445720000191/0001354457-20-000191-index.htm |
| 2019-06-10 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1611747/999999999519001314/9999999995-19-001314-index.htm |
| 2020-01-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1611747/999999999520000075/9999999995-20-000075-index.htm |
| 2020-08-10 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1611747/999999999520002092/9999999995-20-002092-index.htm |